Launch represents Vectura Fertin Pharma's
first medical cannabis CBD lozenge to be
introduced in Canada
Launch follows announcement of commercial
collaboration between Cogent International, a
Vectura Fertin Pharma subsidiary, and Aurora to leverage Aurora's
Canadian medical cannabis
patient platform
Collaboration will explore the potential to
launch Vectura Fertin Pharma's future medical
cannabis portfolio in Canada
EDMONTON, AB, and STAMFORD, Conn., Sept. 9,
2024 /PRNewswire/ - Aurora Cannabis Inc.
("Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based
global medical cannabis company, and Vectura Fertin Pharma, Inc.,
an innovator in wellness and healthcare, are pleased to announce
the launch of the newly developed Luo CBD lozenge.
The high-quality CBD lozenge was developed by Vectura Fertin
Pharma and adheres to stringent safety, quality and regulatory
standards to address unmet medical and health needs. It is the
first of Vectura Fertin Pharma's medical cannabis products to
launch in Canada. The CBD lozenge
is being manufactured, packaged and labelled by Cogent, a Vectura
Fertin Pharma subsidiary, for sale and will be distributed by
Aurora through its leading direct-to-patient e-commerce platform.
The CBD lozenge, which has a novel dissolvable format and is easy
to dose, is now available for patients on Aurora's Canadian medical
cannabis patient platform as authorised by healthcare
professionals.
Miguel Martin, CEO for Aurora
said: "As the leading provider of medical cannabis in
Canada, the launch of the newly
developed Luo CBD lozenge on our platform is a significant and
exciting milestone at the beginning of our strategic collaboration
with Vectura Fertin Pharma. We are committed to bringing innovative
solutions to patients and this launch reinforces our position at
the forefront of Canada's medical
cannabis industry."
Michael Kunst, CEO for Vectura
Fertin Pharma, said: "The launch of our newly developed
Luo CBD lozenge on Aurora's medical cannabis patient platform
closely follows the announcement of our joint commercial
collaboration in August this year, and is testament to our
pioneering approach to science-backed innovation to address unmet
medical and health needs. Aurora has the largest patient platform
in Canada and the launch will
enable us to make a meaningful impact to patients and to validate
our product's proposition through real-world patient data."
Through Aurora's leading patient platform, Cogent will gain
access to patient feedback on the CBD lozenge, which will be used
to validate the product proposition and to build real-world patient
data to inform future products. The two companies will explore
opportunities regarding the potential commercialisation of other
Vectura Fertin Pharma medical cannabis products in Canada.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South America.
Headquartered in Edmonton, Alberta, Aurora is a pioneer in global
cannabis, dedicated to helping people improve their lives. The
Company's adult- use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical
cannabis brands include MedReleaf, CanniMed, Aurora and Whistler
Medical Marijuana Co, as well as international brands, Pedanios,
Bidiol, IndiMed and CraftPlant. Aurora also has a controlling
interest in Bevo Farms Ltd., North America's leading supplier of
propagated agricultural plants. Driven by science and innovation,
and with a focus on high-quality cannabis products, Aurora's brands
continue to break through as industry leaders in the medical,
wellness and adult recreational markets wherever they are launched.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
About Vectura Fertin Pharma
At Vectura Fertin Pharma, we are developing and commercializing
a proprietary pipeline of differentiated products and brands in
wellness and healthcare that address unmet patient and consumer
needs. We have unique R&D capabilities in inhaled and oral
technology, which we are applying across four key areas:
Cannabinoids, Inhaled Therapeutics, Nicotine Replacement Therapy
and Consumer Health. Underpinned by scientific rigor, and patient
and consumer insights, we are passionate about finding new and
better ways to help people take care of their health and wellbeing.
Vectura Fertin Pharma was formed in March
2022 following the acquisition of Fertin Pharma, Vectura
Group PLC and OtiTopic by Philip Morris International. For more
information, visit www.vecturafertinpharma.com or
LinkedIn.
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include, but are not limited to, statements regarding the
launch of Vectura Fertin Pharma's Luo CBD lozenge on the Company's
Canadian medical e-commerce platform, the Company's commitment to
bringing innovative solutions to patients, and the potential to
launch Vectura Fertin Pharma's future medical cannabis portfolio in
Canada.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and nongovernment consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations, management's estimation that SG&A will grow only in
proportion of revenue growth, the ability to expand and maintain
distribution capabilities, the impact of competition, the general
impact of financial market conditions, the yield from cannabis
growing operations, product demand, changes in prices of required
commodities, competition, and the possibility for changes in laws,
rules, and regulations in the industry, epidemics, pandemics or
other public health crises, and other risks, uncertainties and
factors set out under the heading "Risk Factors" in the Company's
annual information form dated June 20,
2024 (the "AIF") and filed with Canadian securities
regulators available on the Company's issuer profile on SEDAR at
www.sedarplus.com and filed with and available on the SEC's website
at www.sec.gov. The Company cautions that the list of risks,
uncertainties and other factors described in the AIF is not
exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-and-vectura-fertin-pharma-inc-announce-launch-of-novel-luo-cbd-lozenge-302241433.html
SOURCE Aurora Cannabis Inc.